Scienture Holdings Holds Exclusive U.S. Distribution Rights For Kindeva Drug Subsidiary Summit BioSciences' Rezenopy Nasal Spray, Which Received A U.S. Patent Effective May 12

Loading news article.

Scienture Holdings Holds Exclusive U.S. Distribution Rights For Kindeva Drug Subsidiary Summit BioSciences' Rezenopy Nasal Spray, Which Received A U.S. Patent Effective May 12 | WAPE

Scienture Holdings Holds Exclusive U.S. Distribution Rights For Kindeva Drug Subsidiary Summit BioSciences' Rezenopy Nasal Spray, Which Received A U.S. Patent Effective May 12

Article summary

Related companies

Comments —